Table 1.
Respondents’ characteristics, N = 410.
| Independent Variables | Categories | Total Sample, N (%) | Booster COVID-19 Vaccination Acceptance | |||
|---|---|---|---|---|---|---|
| Willing to Be Vaccinated | Unwilling to Be Vaccinated | |||||
| 410 (100%) | 315 | 76.8% | 95 | 23.2% | ||
| Sex | Male | 227 (55.4%) | 167 | 73.6% | 60 | 26.4% |
| Female | 183 (44.6%) | 148 | 80.9% | 35 | 19.1% | |
| Age | 18–59 years | 235 (57.3%) | 180 | 76.6% | 55 | 23.4% |
| 60–93 years | 175 (42.7%) | 135 | 77.1% | 40 | 22.9% | |
| Residence | Rural | 268 (65.4%) | 210 | 78.4% | 58 | 21.6% |
| Urban | 142 (34.6%) | 105 | 73.9% | 37 | 26.1% | |
| Education level | Junior high school and below | 277 (67.6%) | 209 | 75.5% | 68 | 24.5% |
| High school and above | 133 (32.4%) | 106 | 79.7% | 27 | 20.3% | |
| Occupation | Farmer | 211 (53.9%) | 173 | 78.3% | 48 | 21.7% |
| Worker | 75 (18.3%) | 59 | 78.7% | 16 | 21.3% | |
| Other | 114 (27.8%) | 83 | 72.8% | 31 | 27.2% | |
| Allergy history | No | 360 (87.8%) | 279 | 77.5% | 81 | 22.5% |
| Yes | 50 (12.2%) | 36 | 72.0% | 14 | 28.0% | |
| Diabetes | Yes | 120 (29.3%) | 86 | 71.7% | 34 | 28.3% |
| No | 290 (70.7%) | 229 | 79.0% | 61 | 21.0% | |
| Hyperlipidemia | Yes | 126 (30.7%) | 96 | 76.2% | 30 | 23.8% |
| No | 284 (69.3%) | 219 | 77.1% | 65 | 22.9% | |
| Hyperuricemia | Yes | 142 (34.6%) | 107 | 72.3% | 41 | 27.7% |
| No | 268 (65.4%) | 208 | 79.4% | 54 | 20.6% | |
| Comorbidity | No comorbidity | 156 (38.0%) | 129 | 82.7% | 27 | 17.3% |
| At least one comorbidity | 254 (62.0%) | 186 | 73.2% | 68 | 26.8% | |
| Disease control | Instability | 47 (11.5%) | 30 | 63.8% | 17 | 36.2% |
| Stability | 363 (88.5%) | 285 | 78.5% | 78 | 21.5% | |
| In treatment | Yes | 345 (84.1%) | 254 | 73.6% | 91 | 26.4% |
| No | 65 (15.9%) | 61 | 93.8% | 4 | 6.2% | |
| Risk perception of COVID-19 | Very High | 42 (10.2%) | 37 | 88.1% | 5 | 11.9% |
| High | 85 (20.7%) | 65 | 76.5% | 20 | 23.5% | |
| Moderate | 127 (31%) | 91 | 71.7% | 36 | 28.3% | |
| Low | 104 (25.4%) | 83 | 79.8% | 21 | 20.2% | |
| Very Low | 52 (12.7%) | 39 | 75.0% | 13 | 25.0% | |
| Proactive consultation | Yes | 307 (74.9%) | 243 | 79.2% | 64 | 20.8% |
| No | 103 (25.1%) | 72 | 69.9% | 31 | 30.1% | |
| Confidence in effectiveness of the COVID-19 vaccines | Useful | 133 (32.4%) | 115 | 86.5% | 18 | 13.5% |
| Possibly useful | 167 (40.7%) | 143 | 85.6% | 24 | 14.4% | |
| Not sure | 95 (23.2%) | 53 | 55.8% | 42 | 44.2% | |
| Useless | 15 (3.7%) | 4 | 26.7% | 11 | 73.3% | |
| Knowledge on the COVID-19 vaccines | Very well | 80 (19.5%) | 70 | 87.5% | 10 | 12.5% |
| Well | 144 (35.1%) | 114 | 79.2% | 30 | 20.8% | |
| Relatively moderate | 144 (35.1%) | 106 | 73.6% | 38 | 26.4% | |
| Unknown | 39 (9.5%) | 25 | 64.1% | 14 | 35.9% | |
| Not at all | 3 (0.7%) | 0 | 0.0% | 3 | 100.0% | |
| Confidence in safety of the COVID-19 vaccines | Very safe | 86 (21%) | 76 | 88.4% | 10 | 11.6% |
| Safe | 221 (53.9%) | 184 | 83.3% | 37 | 16.7% | |
| Moderate | 86 (21%) | 53 | 61.6% | 33 | 38.4% | |
| Unsafe | 16 (3.9%) | 2 | 12.5% | 14 | 87.5% | |
| Very Unsafe | 1 (0.2%) | 0 | 0.0% | 1 | 100.0% | |